For Webcast Replay, Access Entire Live Case at Abiomed Website
Abiomed,
Inc. (NASDAQ: ABMD),
a leading provider of breakthrough heart support technologies, today
announced the webcast of an Impella®
2.5 procedure performed on an 85-year-old male with multi-vessel
disease at Mount Sinai Medical Center, now available and archived on the
Abiomed website (www.abiomed.com).
The webcast was broadcasted live from Mount Sinai Medical Center on July
21, 2009 and presents a successful high-risk percutaneous coronary
intervention (PCI) case with Impella 2.5 support, performed by Samir
Sharma, M.D., director of the catheterization lab (cath lab) and
interventions, and Annapoorna Kini, M.D., associate professor of the
cath lab at Mount Sinai Medical Center.
The patient, an 85-year-old male with multi-vessel disease, had a left
ventricular ejection fraction (LVEF) of 20 percent, meaning that his
heart’s left ventricle was only pumping 20 percent of its volume with
each beat. A normal LVEF typically ranges from 60 – 65 percent. Impella
2.5 was inserted to maintain left ventricular support and provide
hemodynamic stability. “(Impella) gives operators the confidence to
achieve good results without worrying about hemodynamic compromise,”
states Dr. Sharma during the live webcast.
“Mount Sinai Medical Center is renowned for its high volumes and
exceptional outcomes,” said Michael R. Minogue, Chairman, President and
Chief Executive Officer of Abiomed. “We are honored that Impella is
considered one of the primary options for hemodynamic support and
complete revascularization in high-risk PCI cases.”
To view the entire webcast, go to the Abiomed homepage at www.abiomed.com.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support to acute heart failure
patients across the continuum of care in heart recovery. Our products
are designed to enable the heart to rest, heal and recover by improving
blood flow and/or performing the pumping of the heart. For additional
information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release may contain forward-looking statements, including
statements regarding development of Abiomed's existing and new products,
the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual
results may differ materially from those anticipated in these
forward-looking statements based upon a number of factors, including
uncertainties associated with development, testing and related
regulatory approvals, including anticipated future losses, complex
manufacturing, high quality requirements, dependence on limited sources
of supply, competition, technological change, government regulation,
future capital needs and uncertainty of additional financing, and other
risks and challenges detailed in the Company's filings with the
Securities and Exchange Commission, including the Annual Report filed on
Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers
are cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this Release. The Company
undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this
Release or to reflect the occurrence of unanticipated events.
Abiomed, Impella and the Abiomed logo are all trademarks of Abiomed.
Other company and product names may be trademarks of their respective
owners.
Abiomed,
Inc.
Aimee Maillett, 978-646-1553
Public Relations
Specialist
ir@abiomed.com
